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A B S T R A C T
Propolis, a natural product, has important biological properties, however, studies with Por-
tuguese propolis are scarce. Thus, we aimed to characterize the chemical composition and
the antitumoural and antiangiogenic activities of a sample from Pereiro (Portugal).The chemi-
cal profile of our propolis sample (P10.EE) is similar to the poplar propolis type. P10.EE decreased
cell viability of different tumour cells, being less cytotoxic against non-tumoural cells. P10.EE
decreased MDA-MB-231 and DU145 cell proliferation and migration, with cell cycle changes
and increased cell death.The increased glucose consumption and lactate production in MDA-
MB-231 cells is explained by an increased expression of different metabolism-related proteins.
P10.EE induced a decrease in HBMEC cells total biomass and proliferation and decreased
vessel sprouting in the chicken chorioallantoic membrane. Additionally, P10.EE potenti-
ates paclitaxel effect in MDA-MB-231 and DU145 cells. Concluding, P10.EE can be a good
candidate for cancer drug development since it affects different characteristics that dictate
tumorigenesis.
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MSn, high-performance liquid chromatography-mass spectrometry; IC50, half maximal inhibitory concentration; P10.EE, ethanolic extract
(EE) of Pereiro (P) propolis collected in 2010
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1. Introduction
Over the years, natural products have been a rich and a prom-
ising source for discovery of new pharmaceutical agents, since
they are the source of many active compounds, such as poly-
phenols, terpenoids, alkaloids and other nitrogen compounds,
carbohydrates and lipids (Gordaliza, 2007; Manach, Hubert,
Llorach, & Scalbert, 2009). It is estimated that 60% of the world’s
population has a great dependence on plants for medication
(Bankova, 2007). In fact, more than half of the currently exist-
ing drugs are natural compounds or related (Newman & Cragg,
2007) and over 70% of anticancer drugs are derived from natural
compounds (Watanabe, Amarante, Conti, & Sforcin, 2011).This
is an area of research that is growing continuously and is of
enormous interest. Since natural compounds present differ-
ent structural varieties, they can be used to obtain lead
compounds for therapeutic improvement through molecular
modification (Watanabe et al., 2011). Despite the use of
herbs and other natural plant products as interesting
sources of investigation, modified plant products by ani-
mals have been largely ignored and wasted (Umthong,
Phuwapraisirisan, Puthong, & Chanchao, 2011). In the last few
years there has been an increased interest in a modified plant
product produced by bees: propolis or bee glue (Sforcin &
Bankova, 2011).
Propolis, a natural product used since almost immemorial
times, is a complex natural resinous mixture collected from
several plants, buds and exudates by honeybees (Apis mellifera),
that is obtained by mixing beeswax and salivary enzymes with
the collected resin (Bankova, 2005a, 2005b; Bankova, de Castro,
& Marcucci, 2000; Barlak et al., 2011; Fokt, Pereira, Ferreira,
Cunha, & Aguiar, 2010). Generally, propolis is composed of resin,
wax, essential oils, pollen and other substances and it in-
cludes minerals and organic compounds like phenolic acids
or their esters, flavonoids, terpenes, aromatic aldehydes and
alcohols, fatty acids, stilbenes and β-steroids (Bankova, 2005a;
Barlak et al., 2011). Nevertheless, the standardization of the
chemical composition of propolis is difficult since it
depends on the plant sources and on the geographical and cli-
matic conditions of the site of collection (Bankova, 2005a, 2005b;
Barlak et al., 2011; Sforcin & Bankova, 2011). More than 300 com-
pounds were identified using different analytical app-
roaches (Bankova, Popova, Bogdanov, & Sabatini, 2002; Fokt et al.,
2010; Gomez-Caravaca, Gomez-Romero, Arraez-Roman,
Segura-Carretero, & Fernandez-Gutierrez, 2006; Popova et al.,
2004). Propolis samples from Europe, North America and other
temperate zones are mainly composed of flavonoids
(pinocembrin, pinobanksin, quercetin, chrysin and galangin),
phenolic acids and their esters (Bankova et al., 2000; Falcão et al.,
2010) whereas propolis from tropical areas, like Brazil, is com-
posed essentially by prenylated phenylpropanoids and caffeoyl
quinic acids (Bankova et al., 2000). Portuguese propolis, al-
though little studied, appears to be composed of phenolic acids
and flavonoids, similar to the ones found in European samples.
However, it also composed of several other methylated, es-
terified and hydroxylated derivatives of common poplar
flavonoids, such as crysin-5-methyl ether and kaempferol-5-
methyl ether, and rare derivatives of pinocembrin and
pinobanksin that contains in their structure a phenylpropanoic
acid derivative fraction, like pinobanksin-5-methyl-ether-3-O-
pentanoate and pinobanksin-3-O-butyrate or isobutyrate.
Furthermore, the presence of different flavonoid glycosides in
the chemical composition of some Portuguese propolis, like
quercetin-3-O-rutinoside, glucuronide, glucoside or rhamno-
side, kaempferol-3-O-rutinoside, isorhamnetin-O-glucuronide,
quercetin-dimethyl-ether-O-rutinoside or glucuronide and
kaempferol-O-p-coumaroylrhamnoside, turn such national
samples chemically uncommon and different from the tem-
perate propolis type (Falcão et al., 2010, 2012).
Propolis possesses different biological and pharmacologi-
cal actions, including antibacterial and antifungal (Bankova,
Popova, & Trusheva, 2014; Fokt et al., 2010; Ordonez, Zampini,
Moreno, & Isla, 2011; Scazzocchio, D’Auria, Alessandrini, &
Pantanella, 2006; Sforcin & Bankova, 2011; Silva, Rodrigues,
Feas, & Estevinho, 2012), antiviral (Amoros, Simoes, Girre,
Sauvager, & Cormier, 1992; Gekker, Hu, Spivak, Lokensgard,
& Peterson, 2005; Kai et al., 2014), anti-inflammatory (Hu et al.,
2005), antioxidant (Cardoso, Ribeiro, Ferreira, & Cristina Rego,
2011; Miguel, Nunes, Dandlen, Cavaco, & Antunes, 2010; Moreira,
Dias, Pereira, & Estevinho, 2008; Valente, Baltazar, Henrique,
Estevinho, & Carvalho, 2011) and immunomodulatory (Chan,
Cheung, & Sze, 2012; Orsolic & Basic, 2003; Sforcin & Bankova,
2011). In the last few years, several in vitro and in vivo studies
have also shown antitumoural activity of propolis from dif-
ferent geographic origin and of some of its isolated compounds
on various tumour and non-tumour cells (Barlak et al., 2011;
Chan et al., 2012; Lofty, 2006; Umthong et al., 2011; Valente
et al., 2011; Wu et al., 2011). Briefly, this natural product can
block specific oncogenic signalling pathways (e.g. β-catenin,
c-myc, NF-κB and some intermediary of the PI3K/AKT pathway),
which in turn leads to a decrease in cell proliferation and
growth and can also act by decreasing the cancer stem cell
population, increasing apoptosis, exerting antiangiogenic
effects and modulating the tumour microenvironment, more
specifically suppressing the invasion andmigration (Chan et al.,
2012). Results obtained so far allow to confirm the various
propolis biological properties as well as its safety, increasing
the interest in the use of propolis as a functional food and
nutraceutical that may provide a health benefit (Fokt et al.,
2010).
Portuguese propolis has been highly neglected by both bee-
keepers and the scientific community. Hence, the biological
properties of this resin have been little explored and the few
studies available focused the chemical composition (Falcão et al.,
2010, 2012; Miguel et al., 2010), antioxidant activity (Miguel et al.,
2010; Moreira et al., 2008; Valente et al., 2011), and antitumour
activity on renal cell carcinoma (Valente et al., 2011) and human
colorectal cancer (Valença et al., 2013) of a limited number of
samples harvested in some regions of Portugal.
Thus, this study was developed with the aim to analyze the
chemical composition and the antitumoural activity, more spe-
cifically the effects on cell proliferation, cell cycle and death,
migration,metabolism and angiogenesis, of a Portuguese propo-
lis sample collected in an apiary located in the central region
of the country (Pereiro, Guarda). In addition to the scientific
knowledge obtained, such studies allow valuing a product often
neglected even by the beekeepers, therefore helping to value
and to diversify the product offer of an important sector of the
Portuguese economy.
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2. Materials and methods
2.1. Preparation of propolis extracts
Propolis was collected by Pedro Fernandes (Mel do Abel) in 2010
from A. mellifera beehives, by conventional scraping, in an apiary
(Pereiro, N 40° 44′57.135″,W 7° 0′59.403″, elevation: 672,600 m)
located in the central region of Portugal (Beira Alta), in the dis-
trict of Guarda, city of Pinhel. After collection, propolis sample
was frozen at −18 °C. The raw propolis was ground into small
pieces and subsequently extracted with absolute ethanol at
room temperature according to Valença et al. (2013). After ex-
traction, a sample with a dry weight of 26.05 g was obtained.
Ethanolic extract of Pereiro propolis (P10.EE) was dissolved in
dimethyl sulphoxide (DMSO) to a 500 mg/mL stock solution.
2.2. Total polyphenol and flavonoid content analysis
Determination of total phenolic content was performed ac-
cording to the Folin–Ciocalteu colorimetric method (Singleton,
Orthofer, & Lamuela-Raventos, 1999). Quantification of total fla-
vonoid content was performed according to the method
described by Woisky and Salatino (1998). Quercetin was used
as standard for both quantifications.
2.3. HPLC-DAD-ESI-MSn analysis
The HPLC-DAD-ESI-MSn analysis was performed on an Ulti-
mate 3000, Dionex separation module equipped with PDA
(Varian Prostar) detector and coupled to a mass spectrometry
(MS) (Thermo Scientific,Waltham, MA, USA).The column used
was a 250 mm × 4,6 mm id, 5 µm bread diameter, end-capped
Nucleosil C18 (Macherey-Nagel). The mobile phase was com-
posed of two solvents: (A) 0.1% (v/v) formic acid in water, and
(B) acetonitrile. The flow rate was 1 mL/min and spectral data
for all peaks were acquired in the range 200–600 nm.The mass
spectrometry (MS) used was an Amazon SL (Bruker Daltonics,
Bremen, Germany) ion trap MS equipped with an electrospray
ionization (ESI) source. Control and data acquisition were carried
out with the Compass Data Analysis system (Bruker Daltonics).
The nitrogen gas pressure (above 99% purity) was 520 kPa
(75 psi). The instrument was operated in negative-ion mode,
with ESI voltage set at 5.00 kV and the dry temperature at 200 °C.
The full scan covered the mass range from m/z 70 to 700. CID-
MS/MS and MSn experiments were performed on mass-
selected precursor ions using standard isolation and excitation
configuration. Full scan data acquisition was also performed
fromm/z 70 to 700 in MS scan mode.The collision energy used
was between 10 and 40 (arbitrary units).
2.4. Cell lines and cell culture
MDA-MB-231, MDA-MB-468 and MCF7 (breast cancer) were ob-
tained from American Type Culture Collection (ATCC) or from
collections developed by Drs Elena Moisseva (University of Leic-
ester, Leicester, UK), Marc Mareel (Ghent University Hospital,
Belgium) and Eric Lam (Hammersmith Hospital, London, UK).
DU145 and 22RV1 (prostate cancer) and U251 and SW1088 (glio-
blastoma) were obtained from ATCC. Human brain
microvascular endothelial cells (HBMEC) were obtained from
Dr. Kwang Sik Kim (Johns Hopkins University School of Medi-
cine, Baltimore, MD, USA). The immortalized non-tumoural
breast cell line HB4a and the prostate epithelial cell line PNT-1
were provided by Dr. Rui M. Reis (ICVS/3B’s-PT Government As-
sociate Laboratory, Braga, Portugal and Barretos Cancer Hospital,
São Paulo, Brazil) and purchased from the European Collec-
tion of Cell Cultures (ECACC, Salisbury, UK), respectively. A
primary culture of human dermis fibroblasts (hDFb190) was pro-
vided by Mariana Cerqueira and Alexandra Marques (ICVS/
3B’s-PT Government Associate Laboratory, Braga, Portugal).
Breast and brain cancer cell lines and HB4a cells were main-
tained in Dulbecco’s Modified Eagle’s Medium (DMEM 1×, High
Glucose; Gibco, Invitrogen, Scotland, UK) supplemented with
10% foetal bovine serum (FBS) (Gibco, Invitrogen) and 1% of an-
tibiotic (penicillin-streptomycin, 10 µg/mL, Gibco, Invitrogen),
at 37 °C and 5% CO2. Prostate cancer cell lines, HBMEC and PNT-1
cells were maintained in Roswell Park Memorial Institute-
1640 medium (RPMI, Gibco, Invitrogen) and hDFb190 cells were
maintained in Minimum Essential Medium Eagle (MEM) Alpha
Modifications (α-MEM, Gibco, Invitrogen), both media were
supplemented with 10% FBS and antibiotics, as described.
2.5. Cell viability and proliferation assays
The sulphorhodamine B assay (SRB,TOX-6; Sigma-Aldrich Corp.
St. Louis, MO, USA) was used to assess cell viability, accord-
ing to the manufacturer’s recommendations. Briefly, cells were
plated into 96-well plates at a density of 1.5 × 104, 2 × 104 and
1.3 × 104 cells/well for MDA-MB-231, MDA-MB-468 and MCF7 re-
spectively, 8 × 103 cells/well for DU145 and 22RV1, 5 × 103 cells/
well for SW1088, U251 and HBMEC and 1 × 104 cells/well for PNT-
1, HB4a and hDFb190 and allowed to adhere overnight in
complete medium. The effect of the studied propolis ethanol
extract on cell number (total biomass) was determined upon
P10.EE treatment (0.005–0.1 mg/mL) at 24 and 48 hours. Cell pro-
liferation was measured using the 5-bromo-2′-deoxyuridine
(BrdU) Cell Proliferation Assay kit (Cell Proliferation ELISA;
Roche Diagnostics, Pleasanton, CA, USA), as described by
Miranda-Goncalves et al. (2013). Briefly, MDA-MB-231, DU145
and HBMEC cells were plated into 96-well plates (density of
1.5 × 104 and 8 × 103 cells/well), and were treated with 0.0075,
0.015, 0.0035 and 0.007 mg/L and also 0.004 and 0.008 mg/mL
of P10.EE, respectively, during 24 hours in mediumwithout FBS.
Subsequently, cells were incubated with BrdU. Results are ex-
pressed as mean ± SEM of three independent experiments, each
in triplicate.
2.6. Metabolism assay (glucose and
lactate measurement)
MDA-MB-231 (3 × 104 cells/well) and DU145 (2.8 × 104 cells/
well) cells were seeded in 48-well plates and allowed to adhere
overnight in complete medium.Then, cells were treated with
the IC50 value of P10.EE for 48 hours. The culture medium of
the cells was collected after 24 and 48 hours and glucose and
lactate were quantified using commercial kits (Roche and
Spinreact, respectively), according to manufacturers’ proto-
cols. Also, the total protein (expressed as total biomass) was
assessed using the SRB assay, for these time points. Results
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are normalized for control and expressed as total µg/total
biomass.
2.7. Apoptosis and cell cycle assays
Annexin (BD Biosciences) and propidium iodide (Sigma) were
used to determine the apoptotic and necrotic cell popula-
tion. Briefly, MDA-MB-231 and DU145 cells were seeded in T25
flasks (1 × 105 cells/mL), and allowed to adhere overnight in com-
plete medium.Then, after 48 hours of treatment with the IC50
value of P10.EE, cells were collected and Annexin V/PI stain-
ing was performed according to themanufacturer’s instructions.
The percentage of cell death was assessed by flow cytometry
(LSRII model, BD Biosciences) with a total of 20,000 events.The
results were analyzed using the FlowJo software (version 7.6;
Tree Star). For cell cycle study, cells were seeded and treated
at the conditions previously described after 6 hours of serum
starvation. After treatment, cells were collected and stained
as previously described (Martinho et al., 2012). Cell cycle analy-
sis was assessed by flow cytometry with a total of 15,000 events,
and the results were analyzed using the FlowJo software (version
7.6; Tree Star). Results are expressed as mean ± SEM of three
independent experiments, each in triplicate.
2.8. Wound healing assay
MDA-MB-231 and DU145 cells were seeded in a six-well culture
plate, at a density of 1 × 106 cells/well and cultured to at least
95% of confluence.Wound-healing assay was performed as pre-
viously reported by Miranda-Goncalves et al. (2013). Cells were
treated with the IC50 value of P10.EE for 48 hours and specific
scratching sites of the wound areas were photographed at 0,
24 and 48 hours. The relative migration distances were ana-
lyzed using the software QWound (developed at ICVS by the
biomedical engineering team) and data were expressed in %
of migration. Results are expressed as mean ± SEM of three in-
dependent experiments, each in triplicate.
2.9. Chicken Chorioallantoic Membrane (CAM) assay
The CAM assay was performed as previously described by
Miranda-Goncalves et al. (2013). Briefly, on the 10th day of de-
velopment, treatments with 0.1 mg/mL of P10.EE in PBS 1X and
respective controls (1% DMSO) were performed.Then, the effect
of P10.EE on CAM vascularization was assessed on days 14 and
17 of development. The number of blood vessels was counted
in the area inside the ring placed previously in the CAM,
using ImageJ software (version 1.41; National Institutes of
Health, available on the Internet at http://rsb.info.nih.gov/nih-
image/).
2.10. Western blotting
Propolis-treated MDA-MB-231 and DU145 cell lysates were sepa-
rated by SDS-PAGE and transferred to nitrocellulose membrane
as formerly described by Miranda-Goncalves et al. (2013). To
analyze the influence of P10.EE on protein expression, mem-
branes were incubated overnight at 4 °C with the primary
polyclonal antibodies for monocarboxylate transporter 1 (MCT1,
1:500 dilution, sc-365501, Santa Cruz Biotechnology);
monocarboxylate transporter 4 (MCT4, 1:2000 dilution, sc-
50329, Santa Cruz Biotechnology); CD147 (1:200 dilution, sc-
71038, Santa Cruz Biotechnology); hypoxia-inducible factor 1
α (HIF-1α, 1:1000 dilution, 610958, BD Bioscience); pyruvate de-
hydrogenase kinase (PDK, 1:2000 dilution, ab110025, Abcam);
lactate dehydrogenase (LDH-A, 1:2000 dilution, ab101562,
Abcam); pyruvate dehydrogenase (PDH, 1:300 dilution, ab67592,
Abcam); glucose transporter 1 (GLUT1, 1:800 dilution, ab15309-
500, Abcam); carbonic anhydrases IX (CAIX, 1:1000 dilution,
ab15086,Abcam); hexokinases II (HKII, 1:2000 dilution, ab104836,
Abcam); CD44 (1:500 dilution, MCA2726, AbDSerotec). Signals
of the bound antibodies were detected by chemilumines-
cence (Supersignal West Femto kit, Pierce, Thermo Scientific).
β-Actin was used as loading control at 1:300 dilution (sc-
1616; Santa Cruz Biotechnology).
2.11. Drug combination studies
MDA-MB-231 and DU145 cells were seeded into 96-well plates
at a density of 1.5 × 104 and 8 × 103 cells/well, respectively.Treat-
ments with (i) paclitaxel (0.01–1 µM), (ii) P10.EE (0.005–0.1 mg/
mL) and (iii) paclitaxel (0.01–1 µM) + P10.EE (0.0075 or 0.0035 mg/
mL) were done for 48 hours. Additionally, cells were also pre-
treated with P10.EE (0.0075 or 0.0035 mg/mL) for 24 hours,
followed by 24 hours of treatment with paclitaxel (0.01–1 µM)
but no P10.EE.The effect of the drugs on cell viability (total cell
biomass) was evaluated with the SRB assay, as described above.
2.12. Statistical analysis
Results were expressed as mean ± SEM and statistically ana-
lyzed using the GraphPad Prism 5 software. Unpaired t-test was
performed to compare two groups. Significance was consid-
ered as p ≤ 0.05.
3. Results
3.1. Phenolic characterization of P10.EE by UV-visible
spectrophotometry and HPLC-DAD-ESI-MSn
Considering that phenolic compounds are major chemical com-
ponents of propolis (Bankova et al., 2000), as well as central
agents on its beneficial properties (Viuda-Martos, Ruiz-Navajas,
Fernandez-Lopez, & Perez-Alvarez, 2008), we first estimated the
total amounts of phenolic compounds and flavonoids in the
P10.EE extract by spectrophotometric assays, followed by the
elucidation of its main phenolic constituents through HPLC-
DAD-ESI-MSn analysis.The spectrophotometric analysis showed
that P10.EE is enriched in phenolic components, containing a
total amount of phenolics of 252.42 ± 13.44 mg quercetin
equivalent/g extract and a total amount of flavonoids of
51.26 ± 2.39 mg quercetin equivalents/g extract.
Further analysis of P10.EE sample by HPLC-DAD-ESI-MSn
allowed the identification of the main phenolic compounds,
which enclose the flavonoids pinocembrin ([M-H]− at m/z 255,
fraction 15), chrysin ([M-H]− at m/z 253, fraction 16), pinobanksin
([M-H]− at m/z 271, fraction 8) and pinobanksin-3-O-acetate
([M-H]− at m/z 313, fraction 17), as well as the phenolic acids
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caffeic acid ([M-H]− at m/z 179, fraction 1), p-coumaric acid ([M-
H]− at m/z 163, fraction 2) and ferulic acid ([M-H]− at m/z 193,
fraction 3) (see Supplementary Table S1 and Fig. S1). Addition-
ally, P10.EE is also enriched in esterified derivatives of caffeic
acid and p-coumaric acid, with particular prevalence of the first
one.The main caffeic acid derivatives comprised two isomers
of isoprenyl ester ([M-H]− at m/z 247, fractions 12 and 13), one
benzyl ester ([M-H]− at m/z 269, fraction 14), the phenylethyl
ester derivative ([M-H]− at m/z 283, fraction 17) and the dimethyl-
ester derivative ([M-H]− at m/z 207, fraction 4), while the main
detected p-coumaric acid derivative appeared as a methyl ester
([M-H]− at m/z 177, fraction 7).
3.2. Effect of P10.EE in the viability of different cells
In the screening performed with different cells, P10.EE gener-
ally affected the viability of the seven tested cancer cell lines,
with the lowest effect for the two normal cell lines and the
fibroblast cells, which demonstrate that they are less sensi-
tive to P10.EE (Table 1 and see Supplementary Fig. S2).We thus
chose two cell lines for subsequent studies: DU145, the most
sensitive cell line and MDA-MB-231 which is also very sensi-
tive to P10.EE but presents an IC50 twofold higher than the IC50
value calculated for DU145 cells. The concentrations of propo-
lis used were the IC50 values at 48 hours.
3.3. In vitro effect of P10.EE on breast and prostate
cancer cells
The antitumoural effect of P10.EE on breast and prostate cancer
cells was characterized on cell proliferation, cell cycle and death,
migration and metabolism. In Fig. 1A, it is possible to observe
that IC50/2 and IC50 of P10.EE, promoted a significant reduc-
tion in MDA-MB-231 and DU145 cell line proliferation,
respectively, compared to the control, with these effects being
concentration-dependent. Regarding the effect of P10.EE on cell
cycle distribution and cell death it was possible to see (Fig. 1B)
that MDA-MB-231 presented a decrease in the cell popula-
tion of G0/G1 phases and G2/M phases which was accompanied
with an increase in the cell population of S phase, for IC50/2
and IC50, compared to control. Additionally, an increase in cell
population of sub-G0 phase was observed. However, in DU145
cells, there was a significant increase in the cell population of
sub-G0 phase with a decrease in the cell population of the G0/
G1 phases and a slight increase in the cell population of S phase,
compared to control, being the greatest effect obtained at the
highest concentrations.Through theAnnexinV/PI assay (Fig. 1C),
we observed that P10.EE treatment induced cell death in MDA-
MB-231 cells by a significant increase in early apoptotic and
late apoptotic/necrotic cell population for 0.015 mg/mL, com-
pared to the control. Nevertheless, treatment of DU145 cells
with 0.007 mg/mL of P10.EE only promoted a slight increase
in late apoptotic/necrotic cell population.
In what concerns cell migration (Fig. 1D), both concentra-
tions of P10.EE (0.0075 and 0.015 mg/mL) significantly decreased
the MDA-MB-231 cell migration, compared to the control, this
effect being dose-dependent. Additionally, there are signifi-
cant differences between 0.015 mg/mL treatment of 24 and 48
hours. In DU145 cells, both concentrations of P10.EE (0.0035 and
0.007 mg/mL) significantly decreased the cell migration and this
effect seems also to be dose-dependent. Nevertheless, there
are no significant differences between the treatment condi-
tions of 24 and 48 hours.
Our results from the effect of P10.EE on metabolic distur-
bance (Fig. 2A) show that MDA-MB-231 suffered a significant
increase in glucose consumption after 24 and 48 hours of treat-
ment with 0.015 mg/mL P10.EE and in lactate production
after 24 hours treatment with 0.015 mg/mL P10.EE and after
48 h for both P10.EE concentrations. For DU145 cells there was
a significant increase in glucose consumption after 24 and 48
hours of treatment with 0.007 mg/mL P10.EE, and in lactate pro-
duction after 48 hours. To further support these results, the
expression of several proteins that are important to the gly-
colytic phenotype was analyzed (Fig. 2B). Consistent with the
induction of glycolytic metabolism, an increase in the expres-
sion of HIF-1α, PDK, GLUT1, LDH-A and CAIX, was observed in
MDA-MB-231 cells treated with P10.EE. Nevertheless,
there were no alterations in the expression of MCT4, MCT1 and
their chaperones (CD147 and CD44). For DU145 cells no altera-
tions were observed in the expression of the same proteins.
Additionally, the effect of the combination of P10.EE and
paclitaxel was assessed on MDA-MB-231 and DU145 cell vi-
ability. For MDA-MB-231 cells (Fig. 3A) treated with the
combination of P10.EE and paclitaxel for 48 hours, there was
a decrease in the IC50 value (0.025 µM). Furthermore,when cells
were first exposed to the IC50/2 of P10.EE for 24 hours and then
treated for additional 24 hours with different concentrations
of paclitaxel, it was possible to see a higher potentiation of
paclitaxel effect (IC50 0.014 µM). In DU145 cells (Fig. 3B) treated
with the combination of P10.EE and paclitaxel for 48 hours it
was seen that P10.EE potentiated the effect of paclitaxel, de-
creasing its IC50 value (3.7e−5 µM).When cells were pre-exposed
to P10.EE, an increase in the IC50 value (0.08 µM) was observed
and thus there was no enhancement of the effect of paclitaxel.
3.4. Effect of P10.EE on angiogenesis
Regarding the in vitro results (Fig. 4A) it is possible to observe
that HBMEC is sensitive to propolis over time, with the IC50
values being 0.015 mg/mL for 24 hours and 0.008 mg/mL for
48 hours. In what concerns proliferation, P10.EE at 0.004 and
0.008 mg/mL significantly decreased the proliferative
capacity of the cells, being the greatest effect obtained for the
highest concentration tested.
Table 1 – Concentration of P10.EE that inhibits 50% of
cell growth (IC50) in different cells.
Cells IC50 (mg/mL)










hDFb 190 0.06 0.062
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Using the in vivo CAM assay (Fig. 4B), it is possible to observe
that 0.1 mg/mL of P10.EE significantly affects the naturally oc-
curring neovascularization from existing vessels in the CAM.
In fact, a significant decrease in the sprouting vessels is visible
ex ovo, as well as changes in morphology (decreased vessel
width) compared to the control.
4. Discussion
In recent years, the understanding of tumour biology has sig-
nificantly changed the paradigm of cancer therapy and allowed
the identification of new therapeutic targets, with develop-
ment of new methods and therapeutic agents (Luo, Solimini,
& Elledge, 2009). Over the years, natural products have been
used as promising sources for discovery of new pharmaceu-
tical agents (Bankova, 2007; Manach et al., 2009). Propolis, has
beenwidely studied for its biological properties (Fokt et al., 2010),
especially antitumour activity (Barlak et al., 2011; Chan et al.,
2012; Chuu et al., 2012; Lofty, 2006; Umthong et al., 2011; Valente
et al., 2011; Wu et al., 2011); nevertheless, there are only two
studies exploring Portuguese propolis with this purpose (Valença
et al., 2013; Valente et al., 2011).
In the present study we aimed to analyze the chemical com-
position and the antitumoural activity of a Portuguese propolis
sample collected in Pereiro, an apiary located in the district
of Guarda, Beira Alta.
Propolis is composed of a great number of phenolic com-
pounds, with flavonoids and phenolic acids being the most
important classes. Results from the spectrophotometric analy-
Fig. 1 – Effect of P10.EE on breast and prostate cancer cell behaviour. (A) The effect of P10.EE on cell proliferation was
determined by BrdU assay. P10.EE decreased significantly the proliferative capacity of MDA-MB-231 and DU145 cells after
24 h treatment. **p ≤ 0.01; ***p ≤ 0.001, compared to control. (B) Cell cycle distribution was determined by flow cytometry of
iodide propidium stained cells after 48 h of P10.EE treatment, at corresponding IC50 values, for MDA-MB-231 and DU145.
P10.EE induced a decrease in G0/G1 with an increase in S phase population in MDA-MB-231 and significantly increased the
sub-G0 phase population in DU145 cells. *p ≤ 0.05, compared to controls. (C) Cell death analysis was performed by Annexin
V/PI (flow cytometry) after 48 h of treatment with IC50/2 and IC50 values of P10.EE. In MDA-MB-231 cells a significant
increase in cell death was observed whereas there were no differences for DU145. *,#p ≤ 0.05, compared to control. (D) Cell
migration was determined by the scratch-wound healing assay. In MDA-MB-231 cells, only 48 h of P10.EE treatment
decreased cell migration significantly. In DU145 cells, both concentrations of P10.EE significantly decreased the cell
migration. **p ≤ 0.01; ***p ≤ 0.001, compared to control and #p ≤ 0.05, comparing 24 and 48 h treatment conditions. All the
results are expressed as mean ± SEM of at least three independent experiments.
165j o u rna l o f f un c t i ona l f o od s 1 1 ( 2 0 1 4 ) 1 6 0 – 1 7 1
sis of total flavonoid and total phenolic content show that P10.EE
has a high concentration of phenolic compounds and flavo-
noids, identical to those found in other propolis samples of
different geographic origin, more specifically samples of Eu-
ropean countries (Barlak et al., 2011; Mavri et al., 2012; Miguel
et al., 2010; Moreira et al., 2008). As already referred, poplar
propolis samples are composed mainly of the flavonoids
pinocembrin, pinobanksin, chrysin and galangin, the pheno-
lic acids caffeic acid, ferulic acid and cinnamic acid, and their
esters, whereas samples of Brazilian propolis, also often studied,
are composed majorly of prenylated phenylpropanoids,
prenylated p-coumaric acids, acetophenones, diterpenic acids,
caffeoyl quinic acids (Bankova, 2005a; Bankova et al., 2000;
Falcão et al., 2010, 2012). In this study, the HPLC-DAD-ESI-
MSn analysis allowed to confirm that Pereiro’s propolis phenolic
profile corresponds to that of a temperate zone type (“poplar”),
as the flavonoids pinocembrin and chrysin plus several phe-
nolic acids and their derivatives (all known to be predominant
in poplar propolis), were eluted in the major HPLC fraction
(Falcão et al., 2010, 2012; Pellati, Orlandini, Pinetti, & Benvenuti,
2011).
Once the principal compounds of the P10.EE were eluci-
dated, we focused our interest in its antitumoural activity.With
the screening performed in different cells, we can consider that
P10.EE affects the viability of the seven tested cancer cell lines,
with the lowest effect for the two normal cell lines and the
fibroblast cells, with these results being in accordance to the
literature (Chuu et al., 2012; Pratsinis, Kletsas, Melliou, & Chinou,
2010; Umthong et al., 2011; Wu et al., 2011; Xuan et al., 2014).
Umthong et al. (2011) also showed that the hexane extract of
Trigona laeviceps propolis from Thailand has a high cytotoxic
effect against five tested cancer cell lines (Chago, KATO-III,
SW620, BT474 and Hep-G2) but not against the normal cell lines
used (HS27 fibroblast and CH-liver). Despite the variability in
propolis chemical composition, it is well known that samples
of different geographic origins or even isolated compounds can
display identical biological activities (Fokt et al., 2010). Ishihara,
Naoi, Hashita, Itoh, and Suzui (2009) showed that the viabil-
ity of different human colon carcinoma cell lines (HCT116, HT29
and SW480) decreased in a dose-dependent way by ethanol ex-
tracts of Chinese and Brazilian propolis. Ethanol extracts of
propolis from Brazil (Li et al., 2007) and Poland (Szliszka et al.,
Fig. 2 – Effect of P10.EE on the glycolytic metabolism of breast and prostate cancer cell lines. (A) In the MDA-MB-231 cells,
0.015 mg/mL P10.EE significantly increased glucose consumption and lactate production after 24 and 48 h treatment. In
DU145 cells, P10.EE at 0.007 mg/mL significantly increased glucose consumption after 24 and 48 h and only after 48 h did it
significantly increase lactate production. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 compared to control and #p ≤ 0.05; ##p ≤ 0.01,
comparing 24 and 48 h treatment conditions. Results are expressed as mean ± SEM of at least three independent
experiments, each in triplicate. (B) Characterization of the expression of several important proteins to the glycolytic
metabolism in breast and prostate cancer cell lines. Western blot analysis of HIF-1α, PDK, GLUT1, HKII, LDH-A, PDH, MCT1,
MCT4, CD147, CD44, CAIX shows different levels of expression in both cell lines. The molecular weights (kDa) are the
following: 120 kDa for HIF-1α, 44 kDa for PDK, 55 kDa for GLUT1, 102 kDa for HKII, 37 kDa for LDH-A, 43 kDa for PDH,
43 kDa for MCT1, 43 kDa for MCT4, 52 kDa for the highly glycosylated and 43 kDa for low glycosylated form of CD147,
90 kDa for CD44, 55 kDa for CAIX.
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2011a) decreased the viability of the DU145 prostate cancer cells
and a decrease of PC-3 prostate cancer cells viability was pro-
moted by ethanolic extract of Brazilian propolis and dimethyl
sulphoxide and water extracts of Turkish propolis (Barlak et al.,
2011; Li et al., 2007).
From the above results, two cell lines were selected for
further studies on the basis of the greater effect of P10.EE after
48 hours: DU145 andMDA-MB-231. Since it is known that propo-
lis can render its antitumoural effect by different mechanisms
(Chan et al., 2012), we analyzed the effect of P10.EE on prolif-
eration, cell cycle, apoptosis, migration and metabolism of the
chosen cancer cell lines and also propolis effect on angiogen-
esis by using an endothelial cell line and the CAM in vivo model.
The results show that besides leading to a dose-dependent de-
crease in MDA-MB-231 cell proliferation, P10.EE also affected
its cell cycle since it appears to promote a cell cycle arrest at
the S phase. There was a significant increase in the cell popu-
lation of S phase with a concurrent decline in the G0/G1 and
G2/M phases. Regarding cell death, P10.EE induced cell death
in MDA-MB-231 cells by a significant increase in early apoptotic
and late apoptotic/necrotic cell population. These results are
in agreement with the observations of Wu et al. (2011), where
the authors showed that CAPE promoted a decrease in MDA-
MB-231 proliferation by NF-κB down-regulation, an S phase cell
cycle arrest by an increase in the expression of p21 and p27
proteins and a decrease in the expression of Rb, TP53, cyclins
G1, D1, E1 and C, CDK2 and apoptosis by a decreased expres-
sion of anti-apoptotic proteins. Another study showed that cell
proliferation of TW2.6 human oral squamous cell carcinoma
cells was suppressed by CAPE through a decrease in G1 phase
cell population, an increase in G2/M phase cell population and
apoptosis (Kuo et al., 2013). CAPE was also shown to inhibit the
proliferation of the colorectal cell line SW480 by decreasing the
β-catenin, c-myc and cyclin D1 expression (He et al., 2006).
Sulaiman et al. (2012) showed that Iraqi propolis promotes HL-
60 cells apoptosis by down-regulating Bcl-2 proteins and
activating Bax proteins.
Concerning DU145 cells, P10.EE significantly decreased the
proliferative capacity of the cells in a dose-dependent way;
however, the effect of P10.EE in DU145 cell cycle differs greatly
from the effect on MDA-MB-231 cells. Propolis-treated DU145
cells present a significant increase in the cell population of sub-
G0 phase, possibly corresponding to an increase of senescence
or apoptotic state cell population, with a slight increase in the
cell population of S phase and a decrease in the cell popula-
tion of the G0/G1 phases. Such results on the anti-proliferative
effects of P10.EE in DU145 cells are in agreement with the study
of Chuu et al. (2012), which shows that CAPE treatment de-
creased cell proliferation by inhibition of p70S6K and other Akt-
related protein signalling networks. Nevertheless, in contrast
to our results, the authors showed that CAPE significantly
reduces cells in the S-phase and increases cells in G0/G1 popu-
lation phases. Additionally, Li et al. (2007) showed that ethanol
extracts of Brazilian propolis regulate the expression of cyclin
D1, B1 and cyclin dependent kinase (CDK) as well as p21 protein,
affecting the proliferation of human prostate cancer cells. Con-
Fig. 3 – Effect of P10.EE on paclitaxel treatment of breast (A) and prostate (B) cancer cell lines, determined by SRB assay at
48 h. Growth curves for paclitaxel and P10.EE in monotherapy were compared with the different types of combination, and
the IC50 values were calculated (table). (A) For MDA-MB-231 cells, both types of treatment decreased the IC50 value compared
to paclitaxel monotherapy, being the effect more significant when cells were pre-treated with P10.EE for 24 h and then
treated for additional 24 h with different concentrations of paclitaxel. (B) For DU145 cells, a decrease in the IC50 value was
only obtained with the mixture of the drugs. Results are expressed as mean of three independent experiments, each in
triplicate.
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cerning the effects of P10.EE on DU145 cell death, there was a
small induction in late apoptotic/necrotic cell population, again
in accordance to the literature (Szliszka et al., 2011a, 2011b).
In those studies it was demonstrated that propolis, more spe-
cifically from Brazil, sensitizes DU145 cells to a TRAIL-induced
death, enhances the expression of TRAIL-R2 and decreases the
activity of NF-κB in LNCaP cells. Also, a significant activation
of caspase-8 and caspase-3, as well as disruption of the mi-
tochondrial membrane potential, was observed in a co-
treatment with TRAIL and artepillin C (Szliszka et al., 2011a,
2011b; Szliszka, Zydowicz, Mizgala, & Krol, 2012). Addition-
ally, in both cell lines P10.EE significantly decreased the cells’
migratory capacity in a dose-dependent way. Similar results
were obtained by Lee et al. (2008) and Hwang et al. (2006) with
CAPE, which significantly inhibited the expression of MMP-2,
MMP-9 and NF-κB promoting an effective suppression in cell
motility and migration.
To the best of our knowledge, studies on the effect of propo-
lis on glycolytic metabolism of cancer cells are scarce, and
lacking for Portuguese propolis. The present study shows that
P10.EE, at different concentrations, promoted in MDA-MB-
231 and DU145 cell lines a significant increase in glucose
consumption and lactate production rates. In MDA-MB-231 cells,
we observed an increased expression of HIF-1α, PDK, GLUT1,
LDH-A and CAIX, which is consistent with induction of gly-
colytic metabolism. Curiously, these results are in agreement
to the ones obtained by Ueda, Hayashibara, and Ashida (2013),
although some caution should be taken in the comparison of
the two studies as the latter authors tested normal cells instead
of cancer cells, as in the present study. Additionally, a recent
study reported that the cytotoxicity effect of a Portuguese propo-
lis sample from Angra do Heroísmo (Azores) involves
disturbance in tumour cell glycolytic metabolism, seen by a
decrease in glucose consumption and lactate production but
in a different cancer model (Valença et al., 2013). We believe
that these differences among the studies could be the result
of the use of different propolis samples and cell models.
In order to evaluate the effect of P10.EE on angiogenesis,
both in vitro and in vivo studies were performed. Using a brain
endothelial cell line (HBMEC), we observed that P10.EE signifi-
cantly induced a dose- and time-dependent reduction in cell
viability and its proliferative capacity after 24 hours of treat-
ment. These results are also in agreement with the literature
(Ahn et al., 2007; Izuta et al., 2009; Kunimasa et al., 2011; Park,
Ohta, Kumazawa, Jun, & Ahn, 2014). Izuta et al. (2009) showed
that VEGF-induced human umbilical vein endothelial cells
Fig. 4 – Antiangiogenic effect of P10.EE. (A) Effect of P10.EE on HBMEC cell viability and proliferation. P10.EE induced a
reduction of HBMEC cell viability and decreased significantly its proliferative capacity after 24 h treatment. ***p ≤ 0.001,
compared to control. Results are expressed as mean ± SEM of at least three independent experiments, each in triplicate. (B)
In vivo effect of P10.EE on the CAM vascularization of the chicken embryo. CAM was photographed on the 14th day (in ovo)
and 17th (in and ex ovo) of development (12.5× magnification). P10.EE treatment affects the natural sprouting of new vessels
from the existing vessels, compared to control. Blood vessels were counted ex ovo, as described in the Materials and
Methods section. P10.EE significantly decreased the number of vessels, compared with the control group (control group
n = 20; 0.1 mg/mL group n =20). **p ≤ 0.01, compared to control.
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(HUVEC) proliferation was significantly suppressed by Chinese
red propolis and CAPE. Ahn et al. (2007) showed that Brazil-
ian propolis could significantly reduce the number of newly
formed vessels and suppress the proliferation of the HUVEC
in vitro and Kunimasa et al. (2011) proposed that the
antiangiogenic effect of propolis was essentially mediated
through inducing apoptosis in tube-forming endothelial cells
through the inactivation of the survival signal ERK1/2.
In the in vivo CAM assay, P10.EE decreased the number of
naturally occurring neovascularization from existing vessels.
These results are in agreement with the observations of
Daleprane et al. (2012) regarding the evidence that polyphe-
nols have antiangiogenic effects in vitro and ex and in vivo, by
inhibiting effectively VEGF gene expression.
Taking into account the similarities between our results and
the ones of the literature, we hypothesize that the antitumoural
and antiangiogenic effects of Pereiro propolis may be medi-
ated in part by the effect of the most abundant compounds
in the sample, caffeic acid and its derivative CAPE.
Additionally, a combinatory drug study was performed to
assess the influenceof P10.EEonpaclitaxel activity in both cancer
cell lines previously selected. In general,we observed that using
different conditions of treatment – in terms of concentrations
of P10.EE and paclitaxel – the decrease of theMDA-MB-231 and
DU145 cell viability bypaclitaxelwaspotentiated.Similarly,Tolba
et al. (2013) observed that CAPE enhances the antiproliferative
and cytotoxic effects of paclitaxel in prostate cancer.
Overall, apart from the increase in glycolytic metabolism,
the results support the use of P10.EE as a candidate for cancer
drug development since it affects important characteristics that
dictate tumorigenesis – cell proliferation, migration and an-
giogenesis – while also promoting cancer cell death. Even
though the study of Portuguese propolis is still at a very initial
stage, this study contributes to its valorization as a natural re-
source and opens new perspectives for its exploitation in
pharmacology or in the functional food area through the con-
ception of new propolis-based products that will improve health
and likely prevent some chronic diseases.
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